Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInventory AverageInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on Sales

Krystal Biotech (KRYS) Net Margin (2021 - 2025)

Krystal Biotech (KRYS) has disclosed Net Margin for 4 consecutive years, with 48.0% as the latest value for Q4 2025.

  • Quarterly Net Margin fell 196.0% to 48.0% in Q4 2025 from the year-ago period, while the trailing twelve-month figure was 52.65% through Dec 2025, up 2195.0% year-over-year, with the annual reading at 52.64% for FY2025, 2195.0% up from the prior year.
  • Net Margin hit 48.0% in Q4 2025 for Krystal Biotech, down from 81.15% in the prior quarter.
  • In the past five years, Net Margin ranged from a high of 1059.79% in Q1 2021 to a low of 2.06% in Q1 2024.
  • Historically, Net Margin has averaged 212.76% across 4 years, with a median of 40.52% in 2025.
  • Biggest five-year swings in Net Margin: plummeted -91133bps in 2024 and later surged 4873bps in 2025.
  • Year by year, Net Margin stood at 1059.79% in 2021, then plummeted by -98bps to 20.62% in 2023, then surged by 142bps to 49.95% in 2024, then fell by -4bps to 48.0% in 2025.
  • Business Quant data shows Net Margin for KRYS at 48.0% in Q4 2025, 81.15% in Q3 2025, and 39.93% in Q2 2025.